NZ734019A - Novel micro-dystrophins and related methods of use - Google Patents
Novel micro-dystrophins and related methods of useInfo
- Publication number
- NZ734019A NZ734019A NZ734019A NZ73401916A NZ734019A NZ 734019 A NZ734019 A NZ 734019A NZ 734019 A NZ734019 A NZ 734019A NZ 73401916 A NZ73401916 A NZ 73401916A NZ 734019 A NZ734019 A NZ 734019A
- Authority
- NZ
- New Zealand
- Prior art keywords
- micro
- methods
- subject
- muscular dystrophy
- dystrophins
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562104537P | 2015-01-16 | 2015-01-16 | |
| PCT/US2016/013733 WO2016115543A2 (en) | 2015-01-16 | 2016-01-15 | Novel micro-dystrophins and related methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ734019A true NZ734019A (en) | 2023-01-27 |
Family
ID=56406571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ734019A NZ734019A (en) | 2015-01-16 | 2016-01-15 | Novel micro-dystrophins and related methods of use |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10479821B2 (enExample) |
| EP (2) | EP4599851A2 (enExample) |
| JP (4) | JP6832280B2 (enExample) |
| KR (1) | KR102684387B1 (enExample) |
| CN (1) | CN107250364A (enExample) |
| AU (2) | AU2016206518B2 (enExample) |
| CA (1) | CA2972811A1 (enExample) |
| IL (4) | IL315273A (enExample) |
| NZ (1) | NZ734019A (enExample) |
| SG (1) | SG11201705324UA (enExample) |
| WO (1) | WO2016115543A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016206518B2 (en) | 2015-01-16 | 2020-03-05 | University Of Washington | Novel micro-dystrophins and related methods of use |
| GB201507842D0 (en) * | 2015-05-07 | 2015-06-17 | New Royal Holloway & Bedford | Production of large-sized microdystrophins in an AAV-based vector configuration |
| ES3040945T3 (en) | 2015-10-28 | 2025-11-06 | Vertex Pharma | Materials and methods for treatment of duchenne muscular dystrophy |
| KR102877920B1 (ko) | 2015-11-16 | 2025-10-30 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법 |
| MA45477A (fr) | 2016-04-15 | 2019-02-20 | Res Inst Nationwide Childrens Hospital | Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire |
| US20170362635A1 (en) * | 2016-06-20 | 2017-12-21 | University Of Washington | Muscle-specific crispr/cas9 editing of genes |
| CA2971303A1 (en) | 2016-06-21 | 2017-12-21 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
| JOP20190166A1 (ar) * | 2017-01-05 | 2019-07-02 | Univ Texas | استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي |
| BR112019015081A2 (pt) | 2017-01-23 | 2020-03-10 | Rutgers, The State University Of New Jersey | Composições para reduzir a expressão da sarcolipina e prevenir e tratar a distrofia muscular e a cardiomiopatia e os métodos de utilização |
| US10687520B2 (en) | 2017-03-07 | 2020-06-23 | The Board Of Regents Of The University Of Texas System | Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44 |
| JP7162021B2 (ja) * | 2017-03-17 | 2022-10-27 | ニューカッスル ユニバーシティ | 筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達 |
| US11534501B2 (en) | 2017-10-18 | 2022-12-27 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
| TW201936201A (zh) | 2017-12-14 | 2019-09-16 | 美商堅固生物科技公司 | 基因之非病毒生產及遞送 |
| SG11202006722RA (en) | 2018-01-31 | 2020-08-28 | Res Inst Nationwide Childrens Hospital | Gene therapy for limb-girdle muscular dystrophy type 2c |
| EP3780952A4 (en) | 2018-04-16 | 2022-03-09 | The Trustees of the University of Pennsylvania | COMPOSITIONS AND METHODS OF TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY |
| MY208145A (en) | 2018-06-18 | 2025-04-18 | Res Inst Nationwide Childrens Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
| KR20210028162A (ko) | 2018-06-29 | 2021-03-11 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법 |
| AU2019333315B2 (en) | 2018-08-30 | 2022-09-29 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with myocardin and ASCL1 |
| BR112021007480A2 (pt) * | 2018-10-24 | 2021-08-10 | Bristol-Myers Squibb Company | distrofinas miniaturizadas e seus usos |
| US20220031865A1 (en) * | 2018-12-12 | 2022-02-03 | Solid Biosciences Inc. | Combination therapy for treating muscular dystrophy |
| CA3131390A1 (en) | 2019-02-26 | 2020-09-03 | Research Institute Of Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy |
| CA3130196A1 (en) * | 2019-03-25 | 2020-10-01 | Isabelle Richard | Production of large-sized quasidystrophins using overlapping aav vectors |
| CN114207120A (zh) | 2019-05-30 | 2022-03-18 | 坚固生物科技公司 | 重组疱疹病毒载体 |
| US20200405824A1 (en) * | 2019-06-26 | 2020-12-31 | University Of Washington | Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease |
| HRP20240505T1 (hr) | 2019-08-21 | 2024-07-05 | Research Institute At Nationwide Children's Hospital | Dostava alfa-sarkoglikana vektorom povezanim s adenovirusom i liječenje mišićne distrofije |
| CA3153902A1 (en) | 2019-10-16 | 2021-04-22 | Pardis SABETI | Engineered muscle targeting compositions |
| KR20220107222A (ko) * | 2019-11-28 | 2022-08-02 | 리젠엑스바이오 인크. | 마이크로디스트로핀 유전자 치료 작제물 및 이의 용도 |
| WO2021163357A2 (en) * | 2020-02-13 | 2021-08-19 | Tenaya Therapeutics, Inc. | Gene therapy vectors for treating heart disease |
| MY209860A (en) * | 2020-02-13 | 2025-08-07 | Tenaya Therapeutics Inc | Gene therapy vectors for treating heart disease |
| MX2022013477A (es) | 2020-04-29 | 2022-11-30 | Bristol Myers Squibb Co | Distrofinas miniaturizadas con dominios de fusion de espectrina y usos de las mismas. |
| WO2021257595A1 (en) | 2020-06-15 | 2021-12-23 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery for muscular dystrophies |
| WO2022004788A1 (ja) * | 2020-06-30 | 2022-01-06 | 東レ株式会社 | 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤 |
| WO2022076750A2 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns or muscle delivery |
| US20240003898A1 (en) | 2020-10-30 | 2024-01-04 | Pfizer Inc. | Methods for measuring dystrophin in tissue samples |
| RU2767335C1 (ru) * | 2021-03-02 | 2022-03-17 | Общество с ограниченной ответственностью «Марлин Биотех» | Химерные белки на основе утрофина и дистрофина человека и их применение для лечения миодистрофии Дюшенна |
| WO2022216749A1 (en) | 2021-04-05 | 2022-10-13 | Solid Biosciences Inc. | Recombinant herpesvirales vector |
| US20240200093A1 (en) * | 2021-04-09 | 2024-06-20 | University Of Washington | Artificial regulatory cassettes for muscle-specific gene expression |
| CA3216744A1 (en) * | 2021-04-26 | 2022-11-03 | Regenxbio Inc. | Microdystrophin gene therapy administration for treatment of dystrophinopathies |
| US20240358857A1 (en) * | 2021-05-11 | 2024-10-31 | Regenxbio Inc. | Treatment of duchenne muscular dystrophy and combinations thereof |
| EP4108263A3 (en) | 2021-06-02 | 2023-03-22 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
| US20240269329A1 (en) * | 2021-06-07 | 2024-08-15 | University Of Florida Research Foundation, Incorporated | Gene therapy for duchenne muscular dystrophy |
| US20250019721A1 (en) | 2021-08-11 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| KR20240095165A (ko) | 2021-08-11 | 2024-06-25 | 솔리드 바이오사이언시즈 인크. | 근이영양증의 치료 |
| WO2023060269A1 (en) | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for targeted delivery |
| EP4219726A1 (en) | 2021-10-15 | 2023-08-02 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
| WO2023081850A1 (en) | 2021-11-04 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to skeletal muscle |
| CN114316070B (zh) * | 2021-12-29 | 2022-11-15 | 上海勉亦生物科技有限公司 | 用于治疗肌营养不良症的转基因表达盒 |
| EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
| US20250288641A1 (en) * | 2022-04-27 | 2025-09-18 | The Curators Of The University Of Missouri | Micro-dystrophin for heart protection |
| WO2024138158A2 (en) * | 2022-12-23 | 2024-06-27 | Ultragenyx Pharmaceutical Inc. | Method of producing soluble microdystrophin protein and uses of the same |
| AU2024220647A1 (en) | 2023-02-13 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Treatment of muscle related disorders with anti-human cacng1 antibodies |
| WO2024216244A2 (en) | 2023-04-13 | 2024-10-17 | Regenxbio Inc. | Targeting aav capsids, methods of manufacturing and using same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60134786D1 (de) * | 2000-10-06 | 2008-08-21 | Univ Michigan | Mini-dystrophin nukleinsäure- und peptidsequenzen |
| US20070202587A1 (en) | 2002-09-23 | 2007-08-30 | Applied Genetic Technologies Corporation | Recombinant AAV production in mammalian cells |
| EP2298926A1 (en) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| US20080044393A1 (en) * | 2004-07-16 | 2008-02-21 | White Robert L | Retinal dystrophin transgene and methods of use thereof |
| US7436622B2 (en) * | 2006-07-31 | 2008-10-14 | Imation Corp. | Concurrent servo and data track writing |
| JP5575486B2 (ja) * | 2007-01-18 | 2014-08-20 | ユニヴァーシティ オブ ミズーリー−コロンビア | 筋鞘にｎＮＯＳを回復させる合成ミニ／ミクロジストロフィン遺伝子 |
| WO2009097129A1 (en) | 2008-01-29 | 2009-08-06 | Applied Genetic Technologies Corporation | Recombinant virus production using mammalian cells in suspension |
| KR101555083B1 (ko) * | 2008-11-11 | 2015-09-22 | 인터내셔널 비지네스 머신즈 코포레이션 | 제공 장치, 시스템, 서버 장치, 프로그램 및 방법 |
| KR20140035967A (ko) * | 2011-05-26 | 2014-03-24 | 유니버시티 오브 워싱톤 | 세포 및 유전자에 기반한 심장 기능을 개선하는 방법 |
| US20130136729A1 (en) * | 2011-11-11 | 2013-05-30 | University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group | Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors |
| US9624282B2 (en) * | 2012-11-26 | 2017-04-18 | The Curators Of The University Of Missouri | Microdystrophin peptides and methods for treating muscular dystrophy using the same |
| US20150329609A1 (en) * | 2014-03-03 | 2015-11-19 | Sujata Acharjee | Chimeric dystrophin proteins to treat dystrophinopathies |
| EP2960336A1 (en) | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
| AU2016206518B2 (en) * | 2015-01-16 | 2020-03-05 | University Of Washington | Novel micro-dystrophins and related methods of use |
-
2016
- 2016-01-15 AU AU2016206518A patent/AU2016206518B2/en active Active
- 2016-01-15 JP JP2017536343A patent/JP6832280B2/ja active Active
- 2016-01-15 EP EP25169094.7A patent/EP4599851A2/en active Pending
- 2016-01-15 IL IL315273A patent/IL315273A/en unknown
- 2016-01-15 CN CN201680005836.8A patent/CN107250364A/zh active Pending
- 2016-01-15 NZ NZ734019A patent/NZ734019A/en unknown
- 2016-01-15 WO PCT/US2016/013733 patent/WO2016115543A2/en not_active Ceased
- 2016-01-15 SG SG11201705324UA patent/SG11201705324UA/en unknown
- 2016-01-15 IL IL286316A patent/IL286316B2/en unknown
- 2016-01-15 EP EP16738022.9A patent/EP3245291A4/en active Pending
- 2016-01-15 US US15/541,870 patent/US10479821B2/en active Active
- 2016-01-15 CA CA2972811A patent/CA2972811A1/en active Pending
- 2016-01-15 KR KR1020177022718A patent/KR102684387B1/ko active Active
- 2016-01-15 IL IL297239A patent/IL297239B2/en unknown
-
2017
- 2017-06-29 IL IL253246A patent/IL253246B/en unknown
-
2019
- 2019-10-04 US US16/593,833 patent/US11958888B2/en active Active
- 2019-10-04 US US16/593,840 patent/US12421285B2/en active Active
-
2020
- 2020-05-22 AU AU2020203358A patent/AU2020203358B2/en active Active
-
2021
- 2021-02-01 JP JP2021014384A patent/JP7164896B2/ja active Active
-
2022
- 2022-10-14 JP JP2022165111A patent/JP7482549B2/ja active Active
-
2024
- 2024-04-22 JP JP2024068905A patent/JP2024088814A/ja active Pending
-
2025
- 2025-08-22 US US19/307,571 patent/US20250376496A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ734019A (en) | Novel micro-dystrophins and related methods of use | |
| JOP20210231A1 (ar) | مركبات ترابطية مستهدفة كمركبات علاجية | |
| JOP20210207A1 (ar) | مركبات ترابطية مستهدفة | |
| CY1122462T1 (el) | Αντινοηματικο νουκλεϊκο οξυ προς χρηση στη θεραπευτικη αγωγη μυϊκης δυστροφιας του duchenne | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| WO2016106401A3 (en) | Rna agents for p21 gene modulation | |
| LT3807413T (lt) | Raumenims specifinio mikrodistrofino pernaša adenoasocijuoto viruso vektoriumi raumenų distrofijos gydymui | |
| LT3596222T (lt) | Raumeniui specifinis mikrodistrofino pristatymas adenoasocijuoto viruso vektoriaus dėka, skirtas raumenų distrofijai gydyti | |
| PH12019501130A1 (en) | Viral delivery of neoantigens | |
| PL3233129T3 (pl) | Konstrukty kwasu nukleinowego i wektory terapii genowej do zastosowania w leczeniu choroby Wilsona i innych schorzeń | |
| HK1257443A1 (zh) | 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法 | |
| IL252917A0 (en) | Vectors and vectors for gene therapy for use in the treatment of Wilson's disease | |
| PH12012502452A1 (en) | Vectors and sequences for the treatment of diseases | |
| MD4733B1 (ro) | Anticorpi anti-TIGIT | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| WO2015168108A3 (en) | Methods for treating cancer using nucleic targeting mdm2 or mycn | |
| WO2009090639A3 (en) | Sirna compounds and methods of use thereof | |
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| MX2016012558A (es) | Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo. | |
| Cai et al. | The forty years of medical genetics in China | |
| EP4467146A3 (en) | Compositions and methods for enhancing gamma delta t cells in the gut | |
| GB201522416D0 (en) | Wilson's disease gene therapy | |
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| CY1123599T1 (el) | Συνθεσεις και μεθοδοι για τη διορθωση ζωνιαιας μυικης δυστροφιας τυπου 2c με τη χρησιμοποιηση παραλειψης εξονιων | |
| MX357770B (es) | Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JAN 2025 BY ANAQUA SERVICES Effective date: 20231220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JAN 2026 BY ANAQUA SERVICES Effective date: 20250109 |